EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models

Susan Acton, Michelle M O'Donnell, Kalaichitra Periyasamy, Bharat Dixit, Haifeng Eishingdrelo, Colin Hill, R Paul Ross, Laurent Chesnel

Brain, Behavior, and Immunity · 2024

DOI: 10.1016/j.bbi.2024.08.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2024. Verfasst von Susan Acton und 7 weiteren Autor:innen. Beteiligte Einrichtung: Adiso Therapeutics, Concord, MA USA. Electronic address: sacton@adisotx.com. Hauptthemen laut MEDLINE: Bacillus, Neuroinflammatory Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Disarm Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroinflammation is a common component of neurological disorders. In the gut-brain-immune axis, bacteria and their metabolites are now thought to play a role in the modulation of the nervous and immune systems which may impact neuroinflammation. In this respect, commensal bacteria of humans have recently been shown to produce metabolites that mimic endogenous G-protein coupled receptor (GPCR) ligands. To date, it has not been established whether plant commensal bacteria, which may be ingested by animals including humans, can impact the gut-brain-immune axis via GPCR agonism. We screened an isopropanol (IPA) extract of the plant commensal Bacillus velezensis ADS024, a non-engrafting live biotherapeutic product (LBP) with anti-inflammatory properties isolated from human feces, against a panel of 168 GPCRs and identified strong agonism of the lysophosphatidic acid (LPA) receptor LPA3. The ADS024 IPA extracted material (ADS024-IPA) did not agonize LPA2, and only very weakly agonized LPA1. The agonism of LPA3 was inhibited by the reversible LPA1/3 antagonist Ki16425. ADS024-IPA signaled downstream of LPA3 through G-protein-induced calcium release, recruitment of β-arrestin, and recruitment of the neurodegeneration-associated proteins 14-3-3γ, ε and ζ but did not recruit the β isoform. Since LPA3 agonism was previously indirectly implicated in the reduction of pathology in models of Parkinson's disease (PD) and multiple sclerosis (MS) by use of the nonselective antagonist Ki16425, and since we identified an LPA3-specific agonist within ADS024, we sought to examine whether LPA3 might indeed be part of a broad underlying mechanism to control neuroinflammation. We tested oral treatment of ADS024 in multiple models of neuroinflammatory diseases using three models of PD, two models of MS, and a model each of amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and chemo-induced peripheral neuropathy (CIPN). ADS024 treatment improved model-specific functional effects including improvements in motor movement, breathing and swallowing, and allodynia suggesting that ADS024 treatment impacted a universal underlying neuroinflammatory mechanism regardless of the initiating cause of disease. We used the MOG-EAE mouse model to examine early events after disease initiation and found that ADS024 attenuated the increase in circulating lymphocytes and changes in neutrophil subtypes, and ADS024 attenuated the early loss of cell-surface LPA3 receptor expression on circulating white blood cells. ADS024 efficacy was partially inhibited by Ki16425 in vivo suggesting LPA3 may be part of its mechanism. Altogether, these data suggest that ADS024 and its LPA3 agonism activity should be investigated further as a possible treatment for diseases with a neuroinflammatory component.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacillusNeuroinflammatory DiseasesAnimalsMiceHumansDisease Models, AnimalMice, Inbred C57BLMultiple SclerosisMaleEncephalomyelitis, Autoimmune, ExperimentalAnti-Inflammatory Agents

Stichwörter der Autor:innen

14–3-3 proteinsAmyotrophic Lateral SclerosisBacillus velezensisBacteriaChemotherapy-Induced Peripheral NeuropathyGPCRGut-brain-immune axisHuntington’s DiseaseLPA3Multiple SclerosisNeuroinflammationParkinson’s Disease

Substanzen

Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Adiso Therapeutics, Concord, MA USA. Electronic address: sacton@adisotx.com.
  • APC Microbiome Ireland, University College Cork, Cork, Ireland.
  • Pentagrit, Chennai, India.
  • Adiso Therapeutics, Concord, MA USA.
  • BioInvenu Corp., NJ, USA.

Förderung

  • Disarm Therapeutics

Zitieren

APA

Acton, S., O'Donnell, M. M., Periyasamy, K., Dixit, B., Eishingdrelo, H., Hill, C., Paul Ross, R., & Chesnel, L. (2024). LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2024.08.024

Vancouver

Acton S, O'Donnell MM, Periyasamy K, Dixit B, Eishingdrelo H, Hill C, et al. LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models. Brain, Behavior, and Immunity. 2024. doi:10.1016/j.bbi.2024.08.024

BibTeX
@article{Acton2024,
  author = {Acton, Susan and O'Donnell, Michelle M and Periyasamy, Kalaichitra and Dixit, Bharat and Eishingdrelo, Haifeng and Hill, Colin and Paul Ross, R and Chesnel, Laurent},
  title = {LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models},
  journal = {Brain, Behavior, and Immunity},
  year = {2024},
  doi = {10.1016/j.bbi.2024.08.024}
}
Kostenlos starten →